Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas (careHPV)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01539668 |
|
Recruitment Status :
Completed
First Posted : February 27, 2012
Last Update Posted : February 26, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
This study evaluates the women cervical samples through molecular tests in order to:
1. Deploy the test careHPV (hybrid capture test) in mobile unities of the Barretos Cancer Hospital to evaluate their performance;
| Condition or disease |
|---|
| Cervical Cancer Squamous Cell Human Papilloma Virus Infection Human Papilloma Virus-Related Carcinoma Prevention |
Step1: Ambulatory samples First of all the careHPV cervical sample will be collected in specifically tubes, after this, make the cervical sample SurePath collect. Each patient will have two cervical samples. In this moment will be collected 2,000 samples at the Gynecology Department of Barretos Cancer Hospital and the women who be attended in the mobile unit of Barretos surrounding.
Sample1: careHPV The collect will be randomized where 1000 will be collected by the doctor and 1000 by self-sampling. The patient will be oriented by nurse with illustrative material. The self-sampling will be realized like the manufacturing protocol (Qiagen Inc., Gaithersburg, MD).
The cervical sample to cytology (SurePath) will be realized by doctor like a complementary test.
The conditions to store the samples are 15˚C to 30˚C by 2 weeks; 2˚C to 8˚C by 4 weeks; or -20˚C by 2 months to research.
Sample2: SurePath® cytology The cervical sample will be realized like the manufacturing protocol, by doctor. The lamina will be prepared like the equipment manufactory (Becton, Dickinson and Company). The cytological findings will be classifieds like the Bethesda system.
The positives women in careHPV/cytology and the negative careHPV but positive cytology (ASC-US+) will be referred to do the colposcopy (or biopsy) at the Barretos Cancer Hospital.
Step2: Mobiles Unities Samples This step will be collected 3,000 samples to careHPV test and SurePath cytology like a complementary test. The self-sampling won't be made in this step.
The samples will be analyzed in the own mobile unit, during the cities visited. The units involved in the project are that attended Mato Grosso, Goiás, Minas Gerais and Rondônia states, because the significantly number of population assisted.
Step3: HPV genotyping All the positives cases to careHPV test will be submitted to identify the HPV types, then realized at the Molecular Oncology Research Center in the Barretos Cancer Hospital.
| Study Type : | Observational |
| Actual Enrollment : | 5079 participants |
| Time Perspective: | Prospective |
| Official Title: | CareHPV - Hybrid Capture Test on Mobile Unit Program to Improve Cervical Cancer Screening in Brazilian Rural and Remote Areas |
| Study Start Date : | March 2012 |
| Actual Primary Completion Date : | December 2012 |
| Actual Study Completion Date : | February 2014 |
| Group/Cohort |
|---|
|
Pap sampling
Women who have undergone Pap sampling and HPV and cytology analysis. The samples will be collected in Mobile Units and Non-Mobile Units.
|
- HR-HPV presence in the studied population. [ Time Frame: Up to 24 months ]
- The meaning of HPV presence relating with the conventional screening test (Papanicolaou smear), and the pattern of setting cervical lesion (biopsy). [ Time Frame: Up to 12 months ]
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Any women who come to do the Papanicolaou test at the Barretos Cancer Hospital and in the mobile units on the remote Brazilian areas.
Exclusion Criteria:
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01539668
| Brazil | |
| Barretos Cancer Hospital | |
| Barretos, São Paulo, Brazil, 14.784-400 | |
| Barretos Cancer Hospital | |
| Barretos, São Paulo, Brazil, 14784-400 | |
| Principal Investigator: | Adriana T Lorenzi, MSc | ||
| Study Director: | Adhemar Longatto-Filho, PhD | Barretos Cancer Hospital |
| Responsible Party: | Adhemar Longatto-Filho, Coordinator, Barretos Cancer Hospital |
| ClinicalTrials.gov Identifier: | NCT01539668 History of Changes |
| Other Study ID Numbers: |
careHPV_2012 |
| First Posted: | February 27, 2012 Key Record Dates |
| Last Update Posted: | February 26, 2014 |
| Last Verified: | February 2014 |
Keywords provided by Adhemar Longatto-Filho, Barretos Cancer Hospital:
|
Cervical Cancer HPV Secondary prevention |
Additional relevant MeSH terms:
|
Uterine Cervical Neoplasms Virus Diseases Papilloma Papillomavirus Infections Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms |
Uterine Cervical Diseases Uterine Diseases Genital Diseases, Female Neoplasms, Squamous Cell Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type DNA Virus Infections Tumor Virus Infections |